That $1.25B Bris­tol-My­ers IDO1 drug? In­cyte claims a for­mer staffer stole it

Ter­ry Rosen

When Bris­tol-My­ers Squibb agreed to pay up to a jaw-drop­ping $1.25 bil­lion to ac­quire the fledg­ling biotech Flexus back in ear­ly 2015 for the sole pur­pose of gain­ing con­trol of a pre­clin­i­cal IDO1 drug, the math seemed to de­fy every known stan­dard on overnight biotech wind­falls.

The 18-month-old biotech had just lined up a $38 mil­lion round from Klein­er Perkins, Cel­gene and The Col­umn Group. In a world where a 10X pay­off af­ter a few years is con­sid­ered a home run, Bris­tol-My­ers’ $800 mil­lion up­front, with $450 mil­lion in ear­ly-stage mile­stones, for a drug that had yet to go in­to hu­mans was done on a whole new lev­el.

“We had a da­ta set that sug­gest­ed it has the po­ten­tial to be best-in-class, with the abil­i­ty for a part­ner to com­bine it with many oth­er as­sets,” Flexus co-founder Ter­ry Rosen told me at the time. “If you look at any com­pa­ny work­ing in on­col­o­gy, it can po­ten­tial­ly in­crease the val­ue of a whole port­fo­lio of as­sets. It could be mul­ti­plica­tive and that cre­ates a big val­u­a­tion.”

What went large­ly (though not en­tire­ly) un­no­ticed at the time was that a fu­ri­ous In­cyte — the wide­ly rec­og­nized leader in IDO1 now in late-stage test­ing with one of the most close­ly-watched pro­grams in on­col­o­gy — quick­ly went to war over the deal.

The com­pa­ny claimed that Jor­dan Frid­man, a sci­en­tist in its ranks, had sys­tem­at­i­cal­ly lift­ed its IDO1 se­crets be­fore mak­ing his way to Flexus. In a law­suit filed against Rosen and Juan Jaen seek­ing more than a bil­lion dol­lars in dam­ages, In­cyte claimed that Frid­man had been de­mand­ing in­for­ma­tion on their IDO1 work in the three months he re­mained at In­cyte af­ter giv­ing no­tice.

Lat­er in 2014, ac­cord­ing to a law­suit In­cyte filed against Flexus, Frid­man “false­ly told In­cyte’s em­ploy­ees that Flexus did not have an IDO-1 in­hibitor project and that he was no longer work­ing on IDO-1 in­hibitors.” But then he al­leged­ly ad­mit­ted his in­volve­ment lat­er that year.

The News Jour­nal in Delaware cov­ered the case in a big fea­ture to­day, which is like­ly to re­fo­cus con­sid­er­able at­ten­tion on Bris­tol-My­ers’ IDO1 work on BMS-986205, which is now be­ing stud­ied in com­bi­na­tion with its big check­point in­hibitor Op­di­vo. Ac­cord­ing to the re­port, the case is head­ed to court next year.

Lawyers for Rosen and Jaen de­nied the claims and seem ready to fight it out in front of a judge.

In an ab­stract post­ed at AACR last April, Bris­tol-My­ers — which like its ri­vals is part­nered with In­cyte’s IDO1 epaca­do­stat — boast­ed about the clear po­ten­tial they were see­ing in their ear­ly-stage in-house pro­gram. Ac­cord­ing to their ab­stract:

Ev­i­dence of sub­stan­tial serum kyn re­duc­tion was ob­served at dos­es as low as 25 mg QD; in­hi­bi­tion at 100 and 200 mg QD ap­pears greater than that re­port­ed for oth­er in-class com­pounds. In ad­di­tion, we have pre­sent­ed the first ev­i­dence of in­tra­tu­moral kyn re­duc­tion by an IDO1 in­hibitor. These da­ta sug­gest the po­ten­tial of BMS-986205 as an IDO1 in­hibitor with su­pe­ri­or PD prop­er­ties and sup­port fur­ther eval­u­a­tion in com­bi­na­tion with ni­vo.

Ever­cor­eISI’s Umer Raf­fat just days ago put out a note say­ing that he thinks the Bris­tol-My­ers drug could be bet­ter than In­cyte’s — with one cru­cial dif­fer­ence. He wrote: “(R)ather than sim­ply pre­vent the en­zyme’s sub­strate from bind­ing, BMY’s in­hibitor wrecks the whole struc­ture of the ac­tive site, form­ing the ba­sis for a po­ten­tial­ly ir­re­versible in­hibitor.”

The Bris­tol-My­ers drug is now in three dif­fer­ent stud­ies, ac­cord­ing to the list­ings on clin­i­cal­tri­als.gov, in­clud­ing a Phase II rapid-fire set of com­bi­na­tion tests for non-small cell lung can­cer. And Phase I/II da­ta is due at the up­com­ing SITC con­fer­ence in ear­ly No­vem­ber.

Frid­man, who’s not a named par­ty in the law­suit, went on to join an­oth­er Klein­er Perkins start­up called FLX Bio as the CSO. A spokesper­son for the com­pa­ny, though, says he’s left the biotech.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

Pfizer and Merck KGaA have detailed the Phase III data that inspired FDA regulators to designate Bavencio a “breakthrough” for first-line advanced bladder cancer and offered an early glance at how the PD-L1 can help patients with a rare gynecological cancer — carving out niches in the checkpoint space for itself after being shut out of numerous others.

In JAVELIN Bladder 100, Bavencio led to a 31% reduction in risk of death compared to standard care alone. It also extended median survival by more than seven months — a historic feat in this setting, according to investigators at Queen Mary University of London.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.